CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.
Manufacturer of Condoms

November 14, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

Subject: **Submission of Unaudited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Half Year ended September 30, 2026, pursuant to Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Dear Sir/Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFDPoD-2/CIR/P/2024/185 dated December 31, 2024, NSE Circular No. NSE/CML/2025/20 dated April 02, 2025, we wish to inform you that the Board of Directors in its meeting held on Saturday, November 14, 2026 at 04:00 P.M has considered and approved the Unaudited Standalone and Consolidated Financial Results along with the Limited Review Report thereon for the half year ended September 30, 2026 as duly considered and reviewed by the Audit Committee.

Accordingly, we are hereby submitting the Unaudited Standalone and Consolidated Financial Results along with the Limited Review Report thereon for the half year ended September 30, 2026.

Further, the Board Meeting commenced at 04:00 P.M. and concluded at 06:00 P.M. with a vote of thanks.

The said information will also be uploaded on the website of the company https://anonditamedicare.com/

Kindly take the aforesaid on your record.

Thanking you,
Yours Truly
For and on behalf of
Anondita Medicare Limited

MEDICARE LIMITED ★ ANONDITA

Bhawna Bisht
Company Secretary and Compliance Officer
Membership No. A70843



Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001
1960, First Floor, Outram Line, Delhi - 110009
Ph. : 011-42171194 Mob : 9810247478
E-mail : jainchopra.company@gmail.com

Independent Auditor's Limited Review Report on unaudited financial results of Anondita Medicare Limited for the half year ended September 30, 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015

To,
The Board of Directors of Anondita Medicare Limited

We have reviewed the accompanying statement of unaudited financial results of Anondita Medicare Limited for the half year ended September 30, 2026. This Financial statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jain Chopra & Company
Chartered Accountants
FR No. 002198N

Rajesh Kumar

Rajesh Kumar
Partner
M.No. 501860

JAIN CHOPRA & COMPANY ★ NEW DELHI ★ CHARTERED ACCOUNTANTS

Place: New Delhi
Date: 14-11-2026

UDIN: 26501860EINZZV2699

ANONDITA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183
Email:-info@anonditamedicare.com

UNAUDITED STANDALONE FINANCIAL STATEMENT AS AT 30 SEPTEMBER, 2026

Amount in Rs.Lakhs unless stated otherwise

Particulars	As at Sept 30,2026 (Unaudited)	As at Sept 30,2025 (Unaudited)	As at March 31, 2026 (Audited)
I. EQUITY AND LIABLITIES			
1. Shareholders' funds			
(a) Share Capital	1,904.48	1,808.66	1,808.66
(b) Reservs and surplus	19,930.17	7,963.81	9,494.38
(c) Money received against share warrants	739.58		
2. Share application money pending allotment			
3. Non - current liabilities			
(a) Long-term borrowings	4,248.49	1,307.40	2,359.62
(b) Deferred Tax Liability (net)	169.83	24.06	193.52
(c) Other Long term liabilities			
(d) Long Term Provision	26.66	15.13	17.80
4. Current liabilities			
(a) Short-term borrowings	2,533.47	1,738.22	967.80
(b) Trade payables			
A) Total outstanding dues of micro enterprises and small enterprises	164.22	153.00	141.23
B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,041.38	323.64	652.64
(c) Other current liabilities	214.17	265.97	193.85
(d) Short-term Provisions	894.64	732.51	463.62
Total	**31,867.08**	**14,332.39**	**16,293.12**
ASSETS			
1) Non Current Assets			
(a) Property, Plant and Equipment and Intangible assets			
(i) Property, Plant and Equipment	5,295.77	1,275.48	3,907.98
(ii) Intangible assets			
(iii) Capital Work In Progress	7,420.55	1,522.08	4,149.50
(iv) Intangible assets under development			
(b) Non-current Investments	351.58	351.58	351.58
(c) Deferred tax assets (net)			
(d) Long-term loans and advances	317.06	37.66	220.79
(e) Other non - current assets	0.12	0.20	0.16
2) Current Assets			
(a) Current investments			
(b) Inventories	2,043.75	1,103.36	1,349.14
(c) Trade receivables	4,821.52	3,321.36	3,798.80
(d) Cash and Cash Equivalents	9,145.75	3,628.28	954.10
(e) Short-term loans and advances	1,790.40	2,360.94	1,109.75
(f) Other current assets	680.58	731.45	451.32
Total	**31,867.08**	**14,332.39**	**16,293.12**

For & on behalf of Board of Directors
Anondita Medicare Limited

Anupam Ghosh
Managing Director
DIN: 02675517
D-001 Sector 80 Noida U.P

Place:Noida
Dated:14-11-2026

ANONDITA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183
Email:-info@anonditamedicare.com

UNAUDITED STANDALONE STATEMENT OF PROFIT & LOSS AS AT 30 SEPTEMBER, 2026

Amount in Rs.Lakhs unless stated otherwise

PARTICULARS	For the half year ended			For the year ended	
	As at Sept 30,2026 (Unaudited)	As at March 31, 2026 (Audited)	As at Sept 30,2025 (Unaudited)	As at March 31, 2026 (Audited)	As at March 31, 2025 (Audited)
I. Revenue from operations	5,786.31	6,404.56	4,765.06	11,169.62	6,051.52
II. Other Income	90.21	100.35	75.56	175.91	36.38
III. Total Income (I +II)	5,876.52	6,504.91	4,840.62	11,345.53	6,087.90
IV. Expenses:					
Cost of Materials Consumed	2,774.37	2,867.91	2,353.22	5,221.13	3,376.69
Purchase of Stock-in-Trade	-	-			
Change in inventories of finished goods, Work in progress and Stock in Trade	(542.12)	(156.25)	(186.94)	(343.19)	(202.97)
Employee benefit expense	426.87	391.93	271.06	662.99	483.66
Financial costs	231.37	166.95	181.32	348.27	289.46
Depreciation and amortization expense	141.79	67.09	40.03	107.12	74.65
Other expenses	733.15	1,048.63	649.21	1,697.84	605.68
Total Expenses	3,765.43	4,386.25	3,307.91	7,694.16	4,627.17
V. Profit before exceptional and extraordinary items and tax (III - IV)	2,111.09	2,118.66	1,532.71	3,651.37	1,460.73
VI. Exceptional Items					
VII. Profit before extraordinary items and tax (V - VI)	2,111.09	2,118.66	1,532.71	3,651.37	1,460.73
VIII. Extraordinary Items					
IX. Profit before tax (VII - VIII)	2,111.09	2,118.66	1,532.71	3,651.37	1,460.73
X. Tax expense:					
(1) Current tax	486.90	375.12	370.65	745.77	361.15
(2) Income tax for earlier years		38.63		38.63	
(3) Deferred tax Liability / (Assets)	44.94	169.47	15.49	184.96	8.57
XI. Profit(Loss) for the year from continuing operations (IX - X)	1,579.25	1,535.44	1,146.57	2,682.01	1,091.01
XII. Profit/(Loss) from discontinuing operations					
XIII. Tax expense of discounting operations					
XIV. Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)					
XV. Profit/(Loss) for the year (XI + XIV)	1,579.25	1,535.44	1,146.57	2,682.01	1,091.01
XVI. Earning per equity share:					
(1) Basic	8.71	8.49	8.14	16.65	9.70
(2) Diluted	8.71	8.49	8.14	16.65	9.70

For & on behalf of Board of Directors
Anondita Medicare Limited

Anupam Ghosh
Managing Director
DIN: 02675517
D-001 Sector 80 Noida U.P

ANONDITA MEDICARE LIMITED

Place:Noida
Dated:14-11-2026

ANONDITA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183
Email:-info@anonditamedicare.com

UNAUDITED STANDALONE STATEMENT OF CASH FLOW AS AT 30 SEPTEMBER, 2026

Amount in Rs.Lakhs unless stated otherwise

Particulars	As at Sept 30,2026 (Unaudited)	As at Sept 30,2025 (Unaudited)	As at March 31, 2025 (Audited)
Profit before tax	2,111.09	1532.71	3,651.37
Adjustments for:			
Depreciation & amortization expense	141.79	40.03	107.12
Interest expense on borrowings	231.37	181.32	348.27
Interest income	(35.94)	(7.22)	(10.65)
Provision for Gratuity			-
Preliminary exp written off			0.03
Operating Profit before working capital changes	**2,448.31**	**1,746.84**	**4,096.19**
Changes in operating assets and liabilities:			
Increase/(decrease) in trade payables	411.73	124.05	441.29
Increase/(decrease) in other current liabilities	20.32	131.22	59.10
Increase/(decrease) in Short Trem Borrowings	1,565.67	189.88	(580.54)
Increase/(decrease) in Short Trem Provisions	(55.88)	0.10	(319.05)
Increase/(decrease) in Long Trem Provisions	8.86	5.31	7.97
Decrease/(increase) in trade receivables	(1,022.72)	(1,660.94)	(2,138.37)
Decrease/(increase) in Inventory	(694.61)	(207.08)	(452.86)
Decrease/(increase) in Short Term loans and advances	(538.65)	(1,187.59)	(86.76)
Decrease/(increase) in Long Term loans and advances	(96.27)	-	(183.13)
Decrease/(increase) in other current assets	(229.25)	(85.85)	(143.20)
Decrease/(increase) in other Non-current assets	0.04	0.04	
Cash generated from operations	**(630.77)**	**(2,690.85)**	**(3,395.53)**
Income taxes refunded/ (paid)	1,817.54	(944.01)	700.66
Net cash flow from operations (A)	(68.64)	(309.13)	(321.79)
	1,748.90	**(1,253.13)**	**378.86**
Cash flow from investing activities			
Purchase of /Advances for property, plant & equipment and Intangible assets	(4,800.62)	(952.82)	(6,279.83)
Sale of property, plant & equipment			
Investment in Noncurrent Investment			
(Increase)/Decrease in other advance			
Interest received	35.94	7.22	10.65
Purchase of Fixed Assets in acquisition of Business			
Purchase of Investments in acquisition of Business			
Purchase of Advances in acquisition of Business			
Purchase of Trade Receivable in acquisition of Business			
Purchase of Inventories in acquisition of Business			
Purchase of Other Assets in acquisition of Business			
Purchase of Trade advances in acquisition of Business			
Purchase of Trade Payable in acquisition of Business			
Purchase of Other Liabities in acquisition of Business			
Purchase of Borrowings in acquisition of Business			
Purchase of Deferred Tax in acquisition of Business			
Purchase of Provisions in acquisition of Business			
Purchase of Cash & Cash Equivalents in acquisition of Business			
Less: Cash & Cash Equivalents			
Increase/(decrease) in Adavnce to subsidiary	(142.00)		127.01
Net cash used in investing activities (B)	**(4,906.69)**	**(945.60)**	**(6,142.17)**
Cash flow from financing activities			
Proceeds from issue of capital/equity shares			
Further issue of capital	95.82	479.30	479.30
Money received against share warrants	739.58		
Proceeds from share premium	9,006.76	6,470.55	6,470.55
Share issue expenses	(150.21)	(1,083.72)	(1,088.60)
Proceeds/(Repayment) of Long Term Borrowings	1,888.87	116.64	1,168.86
(Repayment)Receipt of borrowing	-		-
Interest paid	(231.37)	(181.32)	(348.27)
Net cash flow from/ (used in) financing activities (C)	**11,349.44**	**5,801.45**	**6,681.84**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	8,191.65	3,602.71	918.53
Cash and cash equivalents at the beginning of the year	954.10	25.56	35.56
Cash and cash equivalents at the closing of the year	**9,145.75**	**3,628.28**	**954.10**
Cash in hand	20.26	11.44	21.86
Balances with banks:			-
- On FDR			610.85
- on other than current acount	9,103.34		144.90
- On current accounts	22.16	3,616.84	176.49
Total	**9,145.75**	**3,628.28**	**954.10**

For & on behalf of Board of Directors
Anondita Medicare Limited

Anupam Ghosh
Managing Director
DIN: 02675517
D-001 Sector 80 Noida U.P

ANONDITA MEDICARE LIMITED

Place:Noida
Dated:14-11-2026

Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001
1960, First Floor, Outram Line, Delhi - 110009
Ph. : 011-42171194 Mob : 9810247478
E-mail : jainchopra.company@gmail.com

Independent Auditor's Limited Review Report on unaudited consolidated financial results of Anondita Medicare Limited for the half year ended September 30, 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015

To,
The Board of Directors of Anondita Medicare Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Anondita Medicare Limited** ("**the Holding Company**") its subsidiary and associate (the Holding Company its subsidiary and associate together referred to as "**the Group**") and its share of the net profit/(loss) after tax for the half year ended September 30, 2026 of its associate ("**the Statement**"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" (AS 25), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India.

   A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

   The Statement includes the results of the following entities:

M/s Anondita Pharma and Latex Limited (Formerly known as- M/s Anondita Healthcare and Rubber Products India Limited)	Subsidiary
M/s Anondita Healthcare (Partnership Firm)	Associate

JAIN CHOPRA & COMPANY * NEW DELHI * CHARTERED ACCOUNTANTS

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in AS 25 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The Statement includes the Group's share of net profit after tax of Rs. 633.06 lacs and Rs. 147.98 lacs for the half year ended September 30, 2026 and half year ended September 30, 2025 respectively as considered in the unaudited consolidated financial results, in respect of an subsidiary referred in para 4 above, whose interim financial statement has not been reviewed by us. This interim financial statement has been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

7. Our conclusion is not modified in respect of this matter.

For Jain Chopra & Company
Chartered Accountants
FR No. 002198N

Rajesh Kumar

Rajesh Kumar
Partner
M.No. 501860

JAIN CHOPRA & COMPANY ★ NEW DELHI ★ CHARTERED ACCOUNTANTS

Place: New Delhi
Date: 14-11-2026

UDIN: 26501860OPPUUW4961

ANONDITA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183
Email:-info@anonditamedicare.com

Unaudited Consolidated Financial Statement as at September 30, 2026

Amount in Rs.Lakhs unless stated otherwise

Particulars	As at Sept 30,2026 (Unaudited)	As at Sept 30,2025 (Unaudited)	As at March 31, 2026 (Audited)
I. EQUITY AND LIABLITIES			
1. Shareholders' funds			
(a) Share Capital	1,904.48	1808.79	1,808.66
(b) Reservs and surplus	22,102.43	9053.54	11,115.06
(c) Minority Interest	272.99	134.39	203.22
(d) Money received against share warrants	739.58		-
2. Share application money pending allotment			-
			-
3. Non - current liabilities			-
(a) Long-term borrowings	4,272.89	1307.40	2,387.03
(b) Deferred Tax Liability (net)	169.83	24.06	193.52
(c) Other Long term liabilities			-
(d) Long Term Provision	26.66	15.13	17.80
			-
4. Current liabilities			-
(a) Short-term borrowings	2,787.95	1773.29	973.12
(b) Trade payables			-
A) Total outstanding dues of micro enterprises and small enterprises	164.22	153.00	141.23
B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,066.17	484.05	661.56
(c) Other current liabilities	294.76	323.39	248.79
(d) Short-term Provisions	1,377.09	974.38	733.14
Total	**35,179.05**	**16,051.43**	**18,483.12**
ASSETS			
1) Non Current Assets			
(a) Property, Plant and Equipment and Intangible assets			
(i) Property, Plant and Equipment	5,297.19	1277.25	3,909.76
(ii) Intangible assets			-
(a) Goodwill	19.18	19.18	19.18
(iii) Capital Work In Progress	7,420.55	1522.08	4,149.50
(iv) Intangible assets under development			-
(b) Non-current Investments	331.40	331.40	331.40
(c) Deferred tax assets (net)	0.25	0.22	0.24
(d) Long-term loans and advances	317.06	37.66	220.79
(e) Other non - current assets	0.12	0.24	0.16
			-
2) Current Assets			-
(a) Current investments			-
(b) Inventories	3,516.88	1450.10	2,075.01
(c) Trade receivables	6,002.32	4809.67	5,185.67
(d) Cash and Cash Equivalents	9,150.99	3650.96	965.19
(e) Short-term loans and advances	2,356.89	2127.18	1,114.56
(f) Other current assets	766.23	825.49	511.66
Total	**35,179.05**	**16051.43**	**18,483.12**

For & On behalf of the Board
Anondita Medicare Limited

ANONDITA MEDICARE LIMITED

Anupam Ghosh
Managing Director
DIN: 02675517
D-001, Sector-80 Noida-201305

Place:Noida
Dated:14-11-2026

ANONDITA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183

Unaudited Consolidated Statement of profit and loss as at September 30 ,2026

Amount in Rs.Lakhs unless stated otherwise

PARTICULARS	For Half Year Ended			For Year ended	
	As at Sept 30,2026 (Unaudited)	As at March 31, 2026 (Audited)	As at Sept 30,2025 (Unaudited)	As at March 31, 2026 (Audited)	As at March 31, 2025 (Audited)
I. Revenue from operations	7,354.17	8,331.87	5,409.70	13,741.57	7,699.07
II. Other Income	60.48	43.46	40.78	84.24	13.88
III. Total Income (I +II)	7,414.64	8,375.33	5,450.48	13,825.81	7,712.95
IV. Expenses:					
Cost of Materials Consumed	2,775.47	2,867.91	2,353.22	5,221.13	3,376.69
Purchase of Stock-in-Trade	1,295.26	1,199.61	164.93	1,364.54	744.86
Change in inventories of finished goods, Work in progress and Stock in Trade	(1,277.67)	(500.33)	(79.18)	(579.51)	(293.20)
Employee benefit expense	461.46	484.75	348.10	832.85	686.80
Financial costs	242.28	171.45	182.35	353.80	291.09
Depreciation and amortization expense	142.15	67.21	40.87	108.09	75.79
Other expenses	830.33	1,133.47	702.49	1,835.95	618.70
Total Expenses	**4,469.28**	**5,424.07**	**3,712.78**	9,136.85	5,500.73
V. Profit before exceptional and extraordinary items and tax (III - IV)	2,945.37	2,951.26	1,737.70	4,688.96	2,212.22
VI. Exceptional Items					
VII. Profit before extraordinary items and tax (V - VI)	2,945.37	2,951.26	1,737.70	4,688.96	2,212.22
VIII. Extraordinary Items					
IX. Profit before tax (VII - VIII)	2,945.37	2,951.26	1,737.70	4,688.96	2,212.22
X. Tax expense:					
(1) Current tax	699.83	594.87	420.42	1,015.29	553.25
(2) IncomeTax for Earlier years		59.08	-	59.08	-
(3) Deferred tax Liability / (Assets)	44.93	169.45	15.49	184.94	8.50
XI. Profit(Loss) for the year from continuing operations (IX - X)	2,200.60	2,127.86	1,301.79	3,429.65	1,650.47
XII. Profit/(Loss) from discontinuing operations					
XIII. Tax expense of discounting operations					
XIV. Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)					
XV. Profit/(Loss) for the year (XI + XIV)	2,200.60	2,127.86	1,301.79	3,429.65	1,650.47
Profit for the Year attributable to					
a. Owners of the Company	2,130.83	2,059.04	1,285.56	3,344.60	1,588.21
b. Minority Interest	69.78	68.82	16.23	85.06	62.26
XVI. Earning per equity share:					
(1) Basic	11.76	11.38	9.08	20.77	14.11
(2) Diluted	11.76	11.38	9.08	20.77	14.11

For & on behalf of Board of Directors
Anondita Medicare Limited

Anupam Ghosh
Managing Director
DIN: 02675517
D-001, Sector-80 Noida-201305

ANONDITA MEDICARE LIMITED

Place:Noida
Dated:14-11-2026

ANONDITA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183

Unaudited Consolidated Statement of Cash Flow as at September 30 ,2026

Amount in Rs.Lakhs unless stated otherwise

Particulars	As at Sept 30,2026 (Unaudited)	As at Sept 30,2025 (Unaudited)	As at March 31, 2026 (Audited)
Profit before tax	2,945.37	1,737.70	4,688.96
Adjustments for:			
Depreciation & amortization expense	142.15	40.87	108.09
Interest expense on borrowings	242.28	247.33	353.80
Interest income	(6.20)	(7.22)	(10.65)
Loss on sale of Car			-
Provision for Gratuity			-
Preliminary exp written off	0.04		0.12
Operating Profit before working capital changes	**3,323.64**	**2,018.68**	**5,140.32**
Changes in operating assets and liabilities:			
Increase/(decrease) in trade payables	427.60	255.52	421.26
Increase/(decrease) in other current liabilities	45.97	113.33	38.72
Increase/(decrease) in Short Trem Provisions	(55.88)	0.10	(511.16)
Increase/(decrease) in Long Trem Provisions	8.86	5.31	7.97
Decrease/(increase) in trade receivables	(816.65)	(2,134.34)	(2,510.34)
Decrease/(increase) in Inventory	(1,441.88)	(99.33)	(717.00)
Decrease/(increase) in Short Term loans and advances	(1,242.33)	(454.33)	(163.95)
Decrease/(increase) in Long Term loans and advances	(96.27)	-	(183.13)
Decrease/(increase) in other current assets	(254.57)	(93.01)	(116.66)
Decrease/(increase) in other Non-current assets	-	0.04	-
	-		
	(3,425.15)	**(2,406.71)**	**(3,734.27)**
Cash generated from operations	(101.51)	(388.03)	1,406.05
Income taxes refunded/ (paid)	(68.64)	(309.13)	(342.24)
Net cash flow from operations (A)	**(170.14)**	**(697.15)**	**1,063.81**
Cash flow from investing activities			
Purchase of /Advances for property, plant & equipment and Intangible assets	(4,800.62)	(953.55)	(6,280.69)
Sale of property, plant & equipment			
Investment in Noncurrent Investment			
(Increase)/Decrease in other advance			
Interest received	6.20	7.22	10.65
Purchase of Fixed Assets in acquisition of Business			
Purchase of Investments in acquisition of Business			
Purchase of Advances in acquisition of Business			
Purchase of Trade Receivable in acquisition of Business			
Purchase of Inventories in acquisition of Business			
Purchase of Other Assets in acquisition of Business			
Purchase of Trade advances in acquisition of Business			
Purchase of Trade Payable in acquisition of Business			
Purchase of Other Liabities in acquisition of Business			
Purchase of Borrowings in acquisition of Business			
Purchase of Deferred Tax in acquisition of Business			
Purchase of Provisions in acquisition of Business			
Purchase of Cash & Cash Equivalents in acquisition of Business			
Less: Cash & Cash Equivalents			
Net cash used in investing activities (B)	**(4,794.43)**	**(946.33)**	**(6,270.04)**
Cash flow from financing activities			
Proceeds from issue of capital/equity shares			
Further Issue of Capital	95.82	479.30	479.30
Money received against share warrants	739.58		
Share Premium	9,006.76	6,470.55	6,470.55
Share Issue Expense	(150.21)	(1,083.72)	(1,088.61)
Proceeds/(Repayment) of Long Term Borrowings	1,885.86	116.64	1,196.26
Increase/(decrease) in Short Trem Borrowings	1,814.84	(473.95)	(575.22)
Interest paid	(242.28)	(247.33)	(353.80)
Net cash flow from/ (used in) financing activities (C)	**13,150.36**	**5,261.50**	**6,128.48**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	8,185.78	3,618.02	922.25
Cash and cash equivalents at the beginning of the year	965.21	32.94	42.94
Cash and cash equivalents at the closing of the year	**9,150.99**	**3,650.96**	**965.19**
Cash in hand	23.34	15.18	25.24
Balances with banks:			
- On FDR			600.11
- on other than current acount	9,103.34		155.64
- On current accounts	24.32	3,635.78	184.20
Total	**9,150.99**	**3,650.96**	**965.19**

For & on behalf of Board of Directors
Anondita Medicare Limited

Anupam Ghosh
Managing Director
DIN: 02675517
D-001, Sector-80 Noida-201305

ANONDITA MEDICARE LIMITED

Place:Noida
Dated:14-11-2026